STAT3 and glioblastoma: Moreover, given that STAT3 activation is responsible for GBM-associated resistance to radiotherapy and Temozolomide chemotherapy, a rational combination regimen can be designed, where 5-AcTMF is used to sensitize GBM cells to radiotherapy and Temozolomide chemotherapy via suppression of STAT3 signaling.